Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > uterine fibroid treatment drugs market
Get a free sample of Uterine Fibroid Treatment Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Uterine Fibroid Treatment Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The key players in the uterine fibroid treatment drugs market are
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Progestin-releasing intrauterine device (IUD) & contraceptives segment registered 65.7% share in 2022 on account of its advantages in managing the uterine fibroids.
Uterine fibroid treatment drugs industry size reached USD 1.7 billion in 2022 and will witness 10% CAGR through 2032 due to the emergence of novel medications for individuals with uterine fibroids.
Pfizer Inc., Abbvie, Inc., AstraZeneca plc, Bayer AG, Myovant Sciences Gmbh, Ferring B.V., Amring Pharmaceuticals Inc., Theramex and Watson Pharma, Inc. are some of the major uterine fibroid treatment drug companies worldwide.
North America uterine fibroid treatment drugs industry will witness 9.4% CAGR through 2023-2032 owing to the increasing demand for non-invasive, safe, and effective treatment options in the region.